Immunotherapy in Small Cell Lung Cancer: Advances, Barriers, and Emerging Strategies
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine disease marked by rapid growth, early metastatic spread, and poor outcomes. The addition of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis to first-line chemotherapy has recently reshaped the treatment landscape f...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2026-02-01
|
| Seria: | Onco |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/2673-7523/6/1/10 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|